Kali, Inc.
KALY
Other OTC0.00
USD
- -
- -
ISIN
US4833801016
CUSIP
483380101
Return %
Stock
S&P500
1Y
0.00
26.53
3Y
499,900.00
76.60
5Y
92,492.59
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Frederick Ferri
- Full Time Employees
- 171
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 8300 Douglas Avenue Dallas TX United States of America 75225
- IPO Date
- Apr 2, 2008
- Website
- kali-extracts.com
- Similar Companies
- Business
- Kali, Inc. (KALY) is a pharmaceutical company engaged in the research, development, and provision of cannabis-based treatments for various illnesses, diseases, and chronic pain conditions. Doing business as Kali-Extracts, Inc., the company offers pharmaceuticals, cannabis extracts derived from its U.S. patented extraction process (U.S. Patent No. 9,199,960), and health and wellness products including CBD-infused consumer items such as candies and drinks; it also provides CBD extraction services for hemp farmers and partners. Kali, Inc. targets the cannabis biopharmaceutical, pharmaceutical, and wellness sectors, serving customers in healthcare, consumer products, and agricultural processing with a focus on therapeutic applications for conditions like chronic obstructive pulmonary disease (COPD). The company, formerly known as VLOV Inc., changed its name to Kali, Inc. in February 2016 and is headquartered at 8300 Douglas Avenue, Suite 800, Dallas, Texas 75225, United States. Its operations are primarily based in the United States, with extraction services initially concentrated in the Northeast region and plans for nationwide expansion. Kali, Inc. employs approximately 171 people and is led by CEO Frederick Ferri. In recent strategic developments, Kali, Inc. acquired a business owning its core patented cannabis extraction process around 2018, enabling entry into the pharmaceutical and concentrates markets; it launched consumer CBD products and extraction contracts generating revenue, targeting $1 million in 2019 sales from these lines. The company formed a joint venture, U.S. Cannabis Health, with Puration, Inc. and Nouveau Life Pharmaceuticals, Inc. in 2018 to develop cannabis pharmaceutical and wellness products, amid a market projected to reach $50 billion by 2029. Further, Kali-Extracts announced restructuring of its cannabis biopharmaceutical business in 2019, a program to certify proprietary CBD extracts as over-the-counter drugs, and a new patent application plus trademark (RespRx) for a CBD formulation targeting COPD and respiratory symptoms in 2020; it also reported exploding demand for extraction services with contracts worth up to $20 million.